Bryam López
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Bryam López has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Joshuan Barboza Meca
Vicerrectorado de Investigación, Universidad Señor de Sipán, Chiclayo 14001, Peru
3 shared publications - Maicol Cortez-Sandoval
Escuela de Medicina Humana, Universidad Científica del Sur, Lima 15067, Peru
3 shared publications - Cesar Bonilla
Vicerrectorado de Investigación, Universidad Señor de Sipán, Chiclayo 14001, Peru
2 shared publications - Oriana Rivera-Lozada
Escuela de Medicina Humana, Universidad Señor de Sipán, Chiclayo 14001, Peru
2 shared publications - Yerson Alberca-Naira
Escuela de Medicina, Universidad Nacional de Piura, Piura 20002, Peru
2 shared publications - Abdias Baltazar Castellanos
Escuela de Enfermeria, Universidad Autónoma del Estado de México, Valle de Chalco 56615, Mexico
1 shared publication
Latest Publications
- Open Access
- 17 September 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (18) , 3014
Diagnostic Accuracy of Artificial Intelligence-Based Electrocardiography for the Detection of Heart Diseases: A Systematic Review and Meta-Analysis
Background/Objectives: Electrocardiography augmented by artificial intelligence (AI-ECG) has been put forward as an inexpensive, scalable means of identifying a wide range of cardiac disorders, but reported performance differs markedly with the condition targeted, the algorithm, and the reference standard. Our pre-specified primary objective was to estimate the diagnostic accuracy of AI-ECG for heart failure/left ventricular systolic dysfunction (HF/LVSD); accuracy in other cardiac conditions was examined condition by condition, and a cross-condition estimate was computed only as a secondary, descriptive summary. Methods: Following the PRISMA-DTA statement, we systematically reviewed diagnostic test accuracy (DTA) studies indexed in PubMed, Scopus, Web of Science, and Embase from inception to 31 March 2026. Eligible records were primary cohort or case–control diagnostic studies applying an AI algorithm to the ECG against an acceptable reference standard, with a reconstructable 2 × 2 table. Screening, extraction, and QUADAS-2 appraisal were performed independently in duplicate. Sensitivity and specificity were pooled with a bivariate random-effects (Reitsma) model whenever four or more studies shared a target condition, with the corresponding hierarchical summary receiver operating characteristic (HSROC) curve; subgroups with fewer than four studies were synthesised descriptively. Pre-specified sensitivity analyses excluded studies at high risk of bias. Certainty was graded with GRADE for test accuracy. Results: Twenty studies (155,442 ECG–reference pairs) were included and 12 (125,568 ECG–reference pairs) entered the quantitative synthesis. In the pre-specified HF/LVSD analysis (k = 5; n = 101,875), pooled sensitivity was 0.86 (95% confidence interval [CI], 0.80–0.90) and pooled specificity was 0.79 (95% CI, 0.70–0.85), with an HSROC area under the curve (AUC) of 0.89; restricting the analysis to the three studies at low risk of bias gave a sensitivity of 0.83 (95% CI, 0.81–0.85) and a specificity of 0.82 (95% CI, 0.75–0.87). The estimated between-study correlation between logit-sensitivity and logit-specificity was −0.86, indicating a strong implicit threshold effect that the bivariate/HSROC framework accommodates. Descriptive subgroup results indicated high accuracy for atrial fibrillation (median sensitivity 0.96, median specificity 0.94; k = 2) and inconsistent performance across coronary disease and acute coronary syndromes (median sensitivity 0.80, median specificity 0.85; k = 2). The secondary cross-condition estimate (k = 12) was 0.84 (95% CI, 0.77–0.89) for sensitivity and 0.87 (95% CI, 0.79–0.93) for specificity (HSROC-AUC 0.92); because it spans heterogeneous targets it is reported as a descriptive summary only. Overall risk of bias was low in 3/20 studies, unclear in 4/20, and high in 13/20, chiefly in the index test and reference standard domains. The Deeks test indicated funnel asymmetry (p = 0.022), which in DTA reviews commonly reflects heterogeneity in true accuracy rather than publication bias. Conclusions: For HF/LVSD, AI-ECG shows consistent and reproducible accuracy against echocardiography, and this estimate proved robust to the exclusion of studies at high risk of bias. Evidence for other cardiac conditions remains condition specific and less certain. Wider adoption would benefit from prospective external validation against guideline-based reference standards, independent adjudication, and transparent reporting of 2 × 2 data at pre-specified operating points.
- 17 September 2026
- Published by MDPI AG in Diagnostics
- Vol. 16 (18) , 3014
Open AccessDiagnostic Accuracy of Artificial Intelligence-Based Electrocardiography for the Detection of Heart Diseases: A Systematic Review and Meta-Analysis
Background/Objectives: Electrocardiography augmented by artificial intelligence (AI-ECG) has been put forward as an inexpensive, scalable means of identifying a wide range of cardiac disorders, but reported performance differs markedly with the condition targeted, the algorithm, and the reference standard. Our pre-specified primary objective was to estimate the diagnostic accuracy of AI-ECG for heart failure/left ventricular systolic dysfunction (HF/LVSD); accuracy in other cardiac conditions was examined condition by condition, and a cross-condition estimate was computed only as a secondary, descriptive summary. Methods: Following the PRISMA-DTA statement, we systematically reviewed diagnostic test accuracy (DTA) studies indexed in PubMed, Scopus, Web of Science, and Embase from inception to 31 March 2026. Eligible records were primary cohort or case–control diagnostic studies applying an AI algorithm to the ECG against an acceptable reference standard, with a reconstructable 2 × 2 table. Screening, extraction, and QUADAS-2 appraisal were performed independently in duplicate. Sensitivity and specificity were pooled with a bivariate random-effects (Reitsma) model whenever four or more studies shared a target condition, with the corresponding hierarchical summary receiver operating characteristic (HSROC) curve; subgroups with fewer than four studies were synthesised descriptively. Pre-specified sensitivity analyses excluded studies at high risk of bias. Certainty was graded with GRADE for test accuracy. Results: Twenty studies (155,442 ECG–reference pairs) were included and 12 (125,568 ECG–reference pairs) entered the quantitative synthesis. In the pre-specified HF/LVSD analysis (k = 5; n = 101,875), pooled sensitivity was 0.86 (95% confidence interval [CI], 0.80–0.90) and pooled specificity was 0.79 (95% CI, 0.70–0.85), with an HSROC area under the curve (AUC) of 0.89; restricting the analysis to the three studies at low risk of bias gave a sensitivity of 0.83 (95% CI, 0.81–0.85) and a specificity of 0.82 (95% CI, 0.75–0.87). The estimated between-study correlation between logit-sensitivity and logit-specificity was −0.86, indicating a strong implicit threshold effect that the bivariate/HSROC framework accommodates. Descriptive subgroup results indicated high accuracy for atrial fibrillation (median sensitivity 0.96, median specificity 0.94; k = 2) and inconsistent performance across coronary disease and acute coronary syndromes (median sensitivity 0.80, median specificity 0.85; k = 2). The secondary cross-condition estimate (k = 12) was 0.84 (95% CI, 0.77–0.89) for sensitivity and 0.87 (95% CI, 0.79–0.93) for specificity (HSROC-AUC 0.92); because it spans heterogeneous targets it is reported as a descriptive summary only. Overall risk of bias was low in 3/20 studies, unclear in 4/20, and high in 13/20, chiefly in the index test and reference standard domains. The Deeks test indicated funnel asymmetry (p = 0.022), which in DTA reviews commonly reflects heterogeneity in true accuracy rather than publication bias. Conclusions: For HF/LVSD, AI-ECG shows consistent and reproducible accuracy against echocardiography, and this estimate proved robust to the exclusion of studies at high risk of bias. Evidence for other cardiac conditions remains condition specific and less certain. Wider adoption would benefit from prospective external validation against guideline-based reference standards, independent adjudication, and transparent reporting of 2 × 2 data at pre-specified operating points.
- Open Access
- 5 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (13) , 5255
Prediction Models for Postoperative Atrial Fibrillation After Cardiac Surgery: A Systematic Review and Critical Appraisal
Background/Objectives: Postoperative atrial fibrillation (POAF) is a frequent complication after cardiac surgery and is associated with increased morbidity, prolonged hospitalization, and higher healthcare costs. Numerous multivariable prediction models have been developed to estimate individual risk; however, their methodological robustness, validation status, and clinical transportability remain uncertain. This systematic review aimed to critically evaluate the methodological quality, validation strategies, and predictive performance of multivariable prediction models developed to estimate the risk of postoperative atrial fibrillation (POAF) after cardiac surgery. Methods: In accordance with PRISMA 2020 guidelines, we conducted a comprehensive search of PubMed, Scopus, Web of Science, and Embase from inception to July 2025. Studies that developed or externally validated multivariable prediction models for POAF in adult patients undergoing cardiac surgery were eligible. Data extraction was performed using the CHARMS checklist, and methodological quality was assessed with PROBAST. Model performance was summarized descriptively, focusing on discrimination (C-statistic/AUC), calibration reporting, and validation strategies. Results: A total of 39 studies were included. Most models were based on logistic regression, whereas a minority employed Cox regression or machine learning techniques. Reported discrimination ranged from 0.60 to 0.98, demonstrating substantial heterogeneity in predictive performance. Calibration was inconsistently reported. Six studies performed external validation. According to PROBAST, 32 of 39 studies (82%) were rated at high risk of bias, predominantly within the analysis domain due to inadequate handling of overfitting, insufficient events-per-variable ratios, and limited validation procedures. Conclusions: Existing prediction models for POAF show variable discrimination but are frequently limited by high risk of bias, inadequate validation, and incomplete calibration assessment, thereby restricting their clinical applicability. Future research should prioritize rigorous external validation, transparent reporting in accordance with TRIPOD recommendations, and methodological strategies that enhance model generalizability and transportability across diverse surgical populations.
- 5 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (13) , 5255
Open AccessPrediction Models for Postoperative Atrial Fibrillation After Cardiac Surgery: A Systematic Review and Critical Appraisal
Background/Objectives: Postoperative atrial fibrillation (POAF) is a frequent complication after cardiac surgery and is associated with increased morbidity, prolonged hospitalization, and higher healthcare costs. Numerous multivariable prediction models have been developed to estimate individual risk; however, their methodological robustness, validation status, and clinical transportability remain uncertain. This systematic review aimed to critically evaluate the methodological quality, validation strategies, and predictive performance of multivariable prediction models developed to estimate the risk of postoperative atrial fibrillation (POAF) after cardiac surgery. Methods: In accordance with PRISMA 2020 guidelines, we conducted a comprehensive search of PubMed, Scopus, Web of Science, and Embase from inception to July 2025. Studies that developed or externally validated multivariable prediction models for POAF in adult patients undergoing cardiac surgery were eligible. Data extraction was performed using the CHARMS checklist, and methodological quality was assessed with PROBAST. Model performance was summarized descriptively, focusing on discrimination (C-statistic/AUC), calibration reporting, and validation strategies. Results: A total of 39 studies were included. Most models were based on logistic regression, whereas a minority employed Cox regression or machine learning techniques. Reported discrimination ranged from 0.60 to 0.98, demonstrating substantial heterogeneity in predictive performance. Calibration was inconsistently reported. Six studies performed external validation. According to PROBAST, 32 of 39 studies (82%) were rated at high risk of bias, predominantly within the analysis domain due to inadequate handling of overfitting, insufficient events-per-variable ratios, and limited validation procedures. Conclusions: Existing prediction models for POAF show variable discrimination but are frequently limited by high risk of bias, inadequate validation, and incomplete calibration assessment, thereby restricting their clinical applicability. Future research should prioritize rigorous external validation, transparent reporting in accordance with TRIPOD recommendations, and methodological strategies that enhance model generalizability and transportability across diverse surgical populations.
- Open Access
- 21 March 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (7) , 2157
Ozenoxacin 1% in Pediatric and Adult Patients with Impetigo: A Meta-Analysis of Randomized Trials
Introduction: Impetigo is a relatively common superficial infection of the skin and soft tissues. Although its prevalence is more significant in childhood, it might also occur in adulthood, affecting the quality of life of our patients. Methods: A systematic review and meta-analysis of randomized controlled trials (RCTs) comparing ozenoxacin 1% with placebo or mupirocin was conducted. Databases searched included PubMed, Embase, Cochrane Library, and ClinicalTrials.gov. Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were estimated using a random-effects model, and heterogeneity was assessed using I2 statistics. Results: Four RCTs with 754 patients met the inclusion criteria. Ozenoxacin significantly improved the clinical success (RR: 1.14, 95% CI: 1.04–1.26, and I2 = 0%) and reduced the clinical failure (RR: 0.54, 95% CI: 0.39–0.75, and I2 = 0%) compared to the placebo. Microbiological success was also superior (RR: 1.31, 95% CI: 1.05–1.58, and I2 = 4%), while the microbiological failure was significantly lower (RR: 0.31, 95% CI: 0.21–0.46, and I2 = 0%). Comparisons with mupirocin showed similar efficacy, though the estimates were less precise. Conclusions: Ozenoxacin 1% is an effective treatment for impetigo, significantly improving clinical and microbiological outcomes while reducing the failure rates compared to the placebo. Its efficacy is comparable to mupirocin, suggesting it as a viable alternative for first-line therapy. Given the low heterogeneity observed, these findings support the clinical use of ozenoxacin for impetigo management. Future large-scale RCTs and direct comparative studies are warranted to further validate its therapeutic benefits.
- 21 March 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (7) , 2157
Open AccessOzenoxacin 1% in Pediatric and Adult Patients with Impetigo: A Meta-Analysis of Randomized Trials
Introduction: Impetigo is a relatively common superficial infection of the skin and soft tissues. Although its prevalence is more significant in childhood, it might also occur in adulthood, affecting the quality of life of our patients. Methods: A systematic review and meta-analysis of randomized controlled trials (RCTs) comparing ozenoxacin 1% with placebo or mupirocin was conducted. Databases searched included PubMed, Embase, Cochrane Library, and ClinicalTrials.gov. Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were estimated using a random-effects model, and heterogeneity was assessed using I2 statistics. Results: Four RCTs with 754 patients met the inclusion criteria. Ozenoxacin significantly improved the clinical success (RR: 1.14, 95% CI: 1.04–1.26, and I2 = 0%) and reduced the clinical failure (RR: 0.54, 95% CI: 0.39–0.75, and I2 = 0%) compared to the placebo. Microbiological success was also superior (RR: 1.31, 95% CI: 1.05–1.58, and I2 = 4%), while the microbiological failure was significantly lower (RR: 0.31, 95% CI: 0.21–0.46, and I2 = 0%). Comparisons with mupirocin showed similar efficacy, though the estimates were less precise. Conclusions: Ozenoxacin 1% is an effective treatment for impetigo, significantly improving clinical and microbiological outcomes while reducing the failure rates compared to the placebo. Its efficacy is comparable to mupirocin, suggesting it as a viable alternative for first-line therapy. Given the low heterogeneity observed, these findings support the clinical use of ozenoxacin for impetigo management. Future large-scale RCTs and direct comparative studies are warranted to further validate its therapeutic benefits.
- Open Access
- 24 December 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 9 (1) , ytae678
When the heart and tumours intertwine: pulmonary hypertension associated with a neuroendocrine tumour—a case report
Background: Pulmonary hypertension caused by extrinsic pulmonary vascular compression secondary to mediastinal neuroendocrine tumours is a very rare condition, posing a diagnostic challenge. There is no clear consensus regarding the best treatment strategy due to the lack of clinical data, leading to poor prognoses for these patients. Case summary: We present the case of a 38-year-old man hospitalized with signs of pulmonary hypertension and acute heart failure. He had experienced progressive dyspnoea over the 12 months prior to admission. Studies performed at our institution revealed dilation of the right heart chambers with right ventricular systolic dysfunction and pulmonary hypertension. Cardiac tomography showed extrinsic vascular compression, leading to emergency endovascular treatment for superior vena cava syndrome, followed by stent implantation in the pulmonary arteries and innominate vein. Further studies identified a mediastinal neuroendocrine tumour, for which chemotherapy was initiated, without clinical response. During outpatient follow-up, cardiac function worsened, and the patient died 48 months after symptoms onset due to a lung infection. Discussion: Pulmonary hypertension secondary to extrinsic vascular compression by mediastinal tumour is a rare condition that presents a diagnostic challenge. This case highlights the importance of considering oncological aetiology in patients with progressive dyspnoea and pulmonary vascular extrinsic compression. Despite early treatment, the prognosis for these patients remains poor.
- 24 December 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 9 (1) , ytae678
Open AccessWhen the heart and tumours intertwine: pulmonary hypertension associated with a neuroendocrine tumour—a case report
Background: Pulmonary hypertension caused by extrinsic pulmonary vascular compression secondary to mediastinal neuroendocrine tumours is a very rare condition, posing a diagnostic challenge. There is no clear consensus regarding the best treatment strategy due to the lack of clinical data, leading to poor prognoses for these patients. Case summary: We present the case of a 38-year-old man hospitalized with signs of pulmonary hypertension and acute heart failure. He had experienced progressive dyspnoea over the 12 months prior to admission. Studies performed at our institution revealed dilation of the right heart chambers with right ventricular systolic dysfunction and pulmonary hypertension. Cardiac tomography showed extrinsic vascular compression, leading to emergency endovascular treatment for superior vena cava syndrome, followed by stent implantation in the pulmonary arteries and innominate vein. Further studies identified a mediastinal neuroendocrine tumour, for which chemotherapy was initiated, without clinical response. During outpatient follow-up, cardiac function worsened, and the patient died 48 months after symptoms onset due to a lung infection. Discussion: Pulmonary hypertension secondary to extrinsic vascular compression by mediastinal tumour is a rare condition that presents a diagnostic challenge. This case highlights the importance of considering oncological aetiology in patients with progressive dyspnoea and pulmonary vascular extrinsic compression. Despite early treatment, the prognosis for these patients remains poor.
- Open Access
- 24 December 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 9 (1) , ytae696
Wait and trust: conservative management of bradyarrhythmias due to dengue infection: a case report
Background: This case report highlights the conduction disorder anomalies associated with dengue infection, particularly bradyarrhythmias due to dysfunction of the sinus node and atrioventricular node, which may require cardiac stimulation such as pacemaker implantation. This case emphasizes the importance of continuous monitoring and the use of additional diagnostic techniques to detect complications in a timely manner. Case summary: A 31-year-old male patient was admitted to our institution with symptoms of dyspnoea, orthopnoea, and severe bradycardia. During hospital admission, atrial fibrillation with a low ventricular response was evident. A 24-h Holter examination revealed additional electrical conduction abnormalities, including first-, second-, and third-degree atrioventricular block, 3.8 s pauses, and migrating atrial rhythm. Since the patient remained asymptomatic and did not present circulatory compromise, conservative management was chosen, with gradual recovery observed during the 30-day follow-up. Discussion: Dengue can significantly affect the cardiovascular system, presenting a variety of abnormalities in cardiac conduction. This case highlights electrical abnormalities and the importance of proper evaluation and management. It was decided to avoid temporary or permanent pacemaker implantation. This case underscores the need for continuous monitoring and the use of alternative diagnostic tools demonstrating that arrhythmias in this context can be successfully managed conservatively.
- 24 December 2024
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 9 (1) , ytae696
Open AccessWait and trust: conservative management of bradyarrhythmias due to dengue infection: a case report
Background: This case report highlights the conduction disorder anomalies associated with dengue infection, particularly bradyarrhythmias due to dysfunction of the sinus node and atrioventricular node, which may require cardiac stimulation such as pacemaker implantation. This case emphasizes the importance of continuous monitoring and the use of additional diagnostic techniques to detect complications in a timely manner. Case summary: A 31-year-old male patient was admitted to our institution with symptoms of dyspnoea, orthopnoea, and severe bradycardia. During hospital admission, atrial fibrillation with a low ventricular response was evident. A 24-h Holter examination revealed additional electrical conduction abnormalities, including first-, second-, and third-degree atrioventricular block, 3.8 s pauses, and migrating atrial rhythm. Since the patient remained asymptomatic and did not present circulatory compromise, conservative management was chosen, with gradual recovery observed during the 30-day follow-up. Discussion: Dengue can significantly affect the cardiovascular system, presenting a variety of abnormalities in cardiac conduction. This case highlights electrical abnormalities and the importance of proper evaluation and management. It was decided to avoid temporary or permanent pacemaker implantation. This case underscores the need for continuous monitoring and the use of alternative diagnostic tools demonstrating that arrhythmias in this context can be successfully managed conservatively.
- Open Access
- 7 April 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (5) , 2093-2096
Pregnancy and complete atrioventricular block: a case report
Introduction: Bradycardia in pregnancy due to complete atrioventricular block (CAVB) is a rare but serious occurrence that can be life-threatening to the mother and fetus. Patients with CAVB may be asymptomatic, but symptomatic cases require urgent and definitive management. Case presentation: The case of a 20-year-old primigravida with previously undiagnosed CAVB who attended the obstetric emergency service in labor is presented. The route of delivery was vaginal without complications. The decision was made to implant a permanent dual-chamber pacemaker on the third day of the puerperium, and the patient did no present cardiovascular symptoms during outpatient follow-up. Clinical discussion: CAVB is a rare but serious condition in pregnancy that can be congenital or acquired. While some cases are relatively benign, others can lead to decompensation and fetal complications. There is no consensus on the best delivery route, but vaginal delivery is generally safe unless contraindicated for obstetric reasons. Pacemaker implantation may be necessary in some cases and can be performed safely during pregnancy. Conclusion: This case highlights the importance of cardiac evaluation in pregnant patients, especially those with a history of syncope. It also highlights the need for adequate and urgent management in symptomatic cases of CAVB in pregnancy and adequate evaluation to decide when to implant the pacemaker as a definitive measure.
- 7 April 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (5) , 2093-2096
Open AccessPregnancy and complete atrioventricular block: a case report
Introduction: Bradycardia in pregnancy due to complete atrioventricular block (CAVB) is a rare but serious occurrence that can be life-threatening to the mother and fetus. Patients with CAVB may be asymptomatic, but symptomatic cases require urgent and definitive management. Case presentation: The case of a 20-year-old primigravida with previously undiagnosed CAVB who attended the obstetric emergency service in labor is presented. The route of delivery was vaginal without complications. The decision was made to implant a permanent dual-chamber pacemaker on the third day of the puerperium, and the patient did no present cardiovascular symptoms during outpatient follow-up. Clinical discussion: CAVB is a rare but serious condition in pregnancy that can be congenital or acquired. While some cases are relatively benign, others can lead to decompensation and fetal complications. There is no consensus on the best delivery route, but vaginal delivery is generally safe unless contraindicated for obstetric reasons. Pacemaker implantation may be necessary in some cases and can be performed safely during pregnancy. Conclusion: This case highlights the importance of cardiac evaluation in pregnant patients, especially those with a history of syncope. It also highlights the need for adequate and urgent management in symptomatic cases of CAVB in pregnancy and adequate evaluation to decide when to implant the pacemaker as a definitive measure.
- Open Access
- 5 March 2023
- Published by Elsevier in Radiology Case Reports
- Vol. 18 (5) , 1848-1851
Coronary artery fistulas as a rare cause of heart failure and ventricular arrhythmia, associated with multiple large vessel fistulas
- 5 March 2023
- Published by Elsevier in Radiology Case Reports
- Vol. 18 (5) , 1848-1851
Open AccessCoronary artery fistulas as a rare cause of heart failure and ventricular arrhythmia, associated with multiple large vessel fistulas